Relief From Side Effects: Clinical Use of Electrodes With Direction

Status Recruiting

Clinical Trial Summary

Deep Brain Stimulation (DBS) uses electrical pulses sent through a lead (insulated wire) to help stop unwanted symptoms in a variety of brain diseases, including the tremor seen in patients with Essential Tremor (ET). The current standard lead allows this stimulation to spread out uniformly in all directions. As these diseases progress, however, the amount of electrical stimulation required to stop the symptom usually increases. This may become problematic because the increased electrical stimulation required for advanced symptoms may spread outside the desired targeted area, and effect other parts of the brain and causing unwanted side effects. A new type of DBS lead has been developed which can steer, or focus, the electrical stimulation in a given direction toward the desired target area and away from areas that would cause side effects. We would like to quantify the benefit seen in patients who have been switched from the traditional lead to this new directional lead.

Clinical Trial Description

Patients implanted with a DBS may experience unwanted side effects such as motor contractures, paresthesia, or dysarthria. This occurs when the electrical field of the stimulation spreads out beyond the targeted area. This is especially common in patients whose disease has progressed, and must use increasingly higher currents in order to regain control of their tremor. Unfortunately, because the electrical field affects neurons in a symmetrical sphere around the DBS, it is often impossible to reach the additional desired neuronal elements without simultaneously affecting equidistant brain regions responsible for side effects. For many of our advanced patients, this means choosing between a debilitating tremor or disabling side effects.The directional lead is a FDA and Health Canada approved DBS lead which features radially segmented electrodes which can selectively steer the electrical field in a predefined direction, orthogonal to the lead trajectory. This will allow DBS clinicians to steer current towards desired structural areas, while avoiding locations, which produce negative side effects. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03795935
Study type	Interventional
Source	University of British Columbia
Contact	Christopher Honey, DPhil
Phone	6048755894
Email	chris.honey@telus.net
Status	Recruiting
Phase	N/A
Start date	September 17, 2018
Completion date	August 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT05381688` - VIM DBS Respiratory Modulation: N-of-1 Trial
Recruiting	`NCT05101161` - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes	N/A
Completed	`NCT02277106` - Evaluate SAGE-547 in Participants With Essential Tremor	Phase 2
Recruiting	`NCT05769933` - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Terminated	`NCT02678429` - Atlas Predicted DBS Settings in Essential Tremor	N/A
Terminated	`NCT02894567` - Evaluation of Directional Recording and Stimulation Using spiderSTN	N/A
Completed	`NCT02523807` - Tremor Monitoring Device	N/A
Active, not recruiting	`NCT02255929` - Gamma Knife Radiosurgery for Treatment of Essential Tremor	N/A
Completed	`NCT01223144` - Decision-making and Emotion Recognition in Essential Tremor	N/A
Completed	`NCT00906412` - Ventrointermediate Nucleus (VIM DBS) and Working Memory	N/A
Recruiting	`NCT05214222` - Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma	Phase 2
Completed	`NCT03051178` - Wearable Sensor for Responsive DBS for ET	N/A
Not yet recruiting	`NCT06036368` - Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor	N/A
Recruiting	`NCT05897775` - Coordinated Reset Deep Brain Stimulation for Essential Tremor	Phase 1
Recruiting	`NCT05968976` - Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET	N/A
Completed	`NCT06314139` - Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized Study.	N/A
Recruiting	`NCT04501133` - Sensory-specific Peripheral Stimulation for Tremor Management	N/A
Active, not recruiting	`NCT03560622` - Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy	N/A
Completed	`NCT00368199` - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes	N/A
Completed	`NCT05480215` - Symptomatic Relief of Action Tremor With Cala Trio Using Trio+ Bands	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Relief From Side Effects: Clinical Use of Electrodes With Direction — RESCUED

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms